Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
56.51 USD | +1.11% | +3.08% | -9.71% |
18/04 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
17/04 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.71% | 4.74B | |
+21.76% | 47.9B | |
+46.62% | 41.42B | |
-2.18% | 40.7B | |
-6.20% | 28.92B | |
+10.19% | 25.55B | |
-20.87% | 19.27B | |
-0.32% | 12.15B | |
+31.04% | 12.14B | |
-0.47% | 11.99B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Piper Sandler Adjusts Price Target on CRISPR Therapeutics to $121 From $115, Reiterates Overweight Rating